IL1A and bacterial vaginosis: More recently, it has been shown that the application of Lactin-V in women treated for BV reduced genital inflammation (i.e., IL1α) and biomarkers of epithelial distress (i.e., soluble E-cadherin), opening up the possibility of employing Lactin-V to reduce HIV susceptibility [269].